Evaluation of safety in terms of unsolicited adverse events and serious adverse events. 7 days after each injection [clinicaltrials_resource:f11b2d17b8479159276f1004fa108838]

Evaluation of safety in terms of unsolicited adverse events and serious adverse events. 7 days after each injection [clinicaltrials_resource:f11b2d17b8479159276f1004fa108838]

MEDI517
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:f11b2d17b8479159276f1004fa108838
Study to Evaluate the Safety and Immunogenicity of MEDI-517P in Healthy Adult Female Volunteers Who Are HPV-16 or HPV-18 DNA Positive [clinicaltrials:NCT00263744]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Evaluation of safety in terms of unsolicited adverse events and serious adverse events. 7 days after each injection [clinicaltrials_resource:f11b2d17b8479159276f1004fa108838]

MEDI517
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:f11b2d17b8479159276f1004fa108838
Bio2RDF identifier
f11b2d17b8479159276f1004fa108838
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:f11b2d17b8479159276f1004fa108838
measure [clinicaltrials_vocabulary:measure]
Evaluation of safety in terms of unsolicited adverse events and serious adverse events.
time frame [clinicaltrials_vocabulary:time-frame]
7 days after each injection
description
identifier
clinicaltrials_resource:f11b2d17b8479159276f1004fa108838
title
Evaluation of safety in terms ...... s. 7 days after each injection
@en
inDataset
type
label
Evaluation of safety in terms ...... b2d17b8479159276f1004fa108838]
@en